US 12,466,805 B2
Pharmaceutical compounds
Peter Hewitt, Craigavon (GB); Mary Melissa Mcfarland, Craigavon (GB); James Samuel Shane Rountree, Craigavon (GB); Frank Burkamp, Craigavon (GB); Christina Bell, Craigavon (GB); Lauren Proctor, Craigavon (GB); Matthew Duncan Helm, Craigavon (GB); Colin O'Dowd, Craigavon (GB); and Timothy Harrison, Craigavon (GB)
Assigned to ALMAC DISCOVERY LIMITED, Craigavon (GB)
Filed by ALMAC DISCOVERY LIMITED, Craigavon (GB)
Filed on Jul. 6, 2021, as Appl. No. 17/368,290.
Application 17/368,290 is a continuation of application No. 16/319,961, granted, now 11,053,213, previously published as PCT/GB2017/052178, filed on Jul. 26, 2017.
Claims priority of application No. 1612938 (GB), filed on Jul. 26, 2016.
Prior Publication US 2022/0002264 A1, Jan. 6, 2022
Int. Cl. A61P 21/00 (2006.01); A61P 25/16 (2006.01); A61P 35/00 (2006.01); C07D 401/04 (2006.01); C07D 401/06 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 409/14 (2006.01); C07D 413/14 (2006.01); C07D 417/14 (2006.01); C07D 491/10 (2006.01)
CPC C07D 401/06 (2013.01) [A61P 21/00 (2018.01); A61P 25/16 (2018.01); A61P 35/00 (2018.01); C07D 401/04 (2013.01); C07D 401/14 (2013.01); C07D 405/14 (2013.01); C07D 409/14 (2013.01); C07D 413/14 (2013.01); C07D 417/14 (2013.01); C07D 491/10 (2013.01)] 22 Claims
 
1. A compound of formula (I):

OG Complex Work Unit Chemistry
including a pharmaceutically acceptable salt, tautomer, stereoisomer or N-oxide derivative thereof, wherein:
R1 is an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, alkylcycloalkyl, heterocycloalkyl, alkylheterocycloalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl group;
R2 is H or an optionally substituted alkyl group,
R3 is H or an optionally substituted alkyl group,
R4 is H or an optionally substituted alkyl group,
R5 is H or an optionally substituted alkyl group,
R2 and R4 may be joined to one another to form an optionally substituted cycloalkyl or heterocycloalkyl that includes the carbon to which they are attached,
R4 and R5 may be joined to one another to form an optionally substituted cycloalkyl or heterocycloalkyl that includes the carbon to which they are attached;
R6 is H or an optionally substituted alkyl group;
W is C or N;
X is CR8, wherein R8 is H or optionally substituted C1-C6 alkyl,
Y is N or CR9
Z is CH, or NH,
wherein R9 is H or optionally substituted alkyl, amido, amino, aryl, heteroaryl, cycloalkyl, cycloheteroalkyl, halo, carbonyl, ester, aminoalkyl, or cyano;
R7 is hydrogen, halo, or an optionally substituted alkyl, alkenyl, alkynyl, amino, aryl, cycloalkyl, cycloalkenyl, alkoxy, aryloxy, heteroaryl or heterocycloalkyl group;
or the compound

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt, tautomer, stereoisomer or N-oxide derivative thereof.